+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biosimilar Contract Manufacturing Market Size, Share & Trends Analysis Report by Source (Mammalian, Non-mammalian), Therapeutic Area (Oncology, Blood Disorders), Service, and Region with Growth Forecasts, 2025-2033

  • PDF Icon

    Report

  • 180 Pages
  • September 2025
  • Region: Global
  • Grand View Research
  • ID: 6176705
REQUEST CUSTOMIZATION
Description Jump to:
The global biosimilar contract manufacturing market size was estimated at USD 8.91 Billion in 2025 and is projected to reach USD 25.19 billion by 2033, growing at a CAGR of 13.87% from 2025 to 2033. The increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is driving demand for affordable biologics.

Biosimilars offer cost-effective alternatives to expensive branded biologics, making them highly suitable for healthcare systems and patients. Pharmaceutical companies are increasingly outsourcing biosimilar production to contract manufacturing organizations (CMOs) to reduce operational costs, ensure regulatory compliance, and accelerate time-to-market. This growing demand and patent expirations of blockbuster biologics fuel strong market expansion for contract manufacturing services, enabling drug developers to focus on innovation while leveraging CMOs’ expertise in large-scale, efficient biosimilar production.

In addition, expiration of patents for blockbuster biologics such as monoclonal antibodies, insulin analogs, and growth factors has opened significant opportunities for biosimilar manufacturers. With billions of dollars in biologics revenue at stake, pharmaceutical companies are increasingly racing to develop biosimilars to capture market share. However, due to high production complexity, many companies rely on contract manufacturing organizations (CMOs) with specialized expertise in biologics development, scale-up, and regulatory compliance. This trend accelerates outsourcing partnerships, enabling faster biosimilar launches while reducing risks and operational costs, thereby driving market growth.

Furthermore, contract manufacturing organizations are heavily investing in advanced biomanufacturing technologies, including single-use systems, high-capacity bioreactors, and continuous processing, to meet the rising demand for biosimilars. These technological advancements enhance efficiency, flexibility, and scalability, attracting pharmaceutical companies to partner with CMOs. In addition, CMOs are expanding global facilities to comply with regional regulatory standards, supporting multinational drug launches. Such expansions enable biosimilar developers to overcome infrastructure limitations, reduce upfront investment costs, and accelerate commercialization timelines. The increasing sophistication and global footprint of CMOs make them indispensable partners, propelling market growth.

Besides these, supportive regulatory environments in key markets such as the U.S., Europe, and emerging economies are fostering the adoption of biosimilars. Regulatory agencies such as the U.S. FDA and EMA have established streamlined approval pathways, ensuring safety and efficacy while expediting market entry. These frameworks encourage investment in biosimilar development, driving demand for high-quality manufacturing partners. Contract manufacturing organizations benefit from their expertise in adhering to stringent regulatory standards, providing companies with compliance assurance and global market access. As regulatory clarity improves worldwide, the reliance on CMOs for biosimilar production is expected to intensify, boosting market growth further.

Global Biosimilar Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global biosimilar contract manufacturing market report based on source, service, therapeutic area, and region

Source Outlook (Revenue, USD Million, 2021-2033)

  • Mammalian
  • Non-mammalian

Service Outlook (Revenue, USD Million, 2021-2033)

  • Recombinant Non-glycosylated Proteins
  • Recombinant Glycosylated Proteins

Therapeutic Area Outlook (Revenue, USD Million, 2021-2033)

  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic & Autoimmune Disorders
  • Rheumatoid Arthritis
  • Others

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segmental and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Biosimilar Contract Manufacturing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Model Analysis
3.4. Product Pipeline Analysis
3.5. Service Pricing Model Analysis
3.6. Technological Advancements
3.7. Supply Chain Analysis
3.8. Biosimilar Contract Manufacturing Market Analysis Tools
3.8.1. Porter’s Five Forces Analysis
3.8.2. PESTEL by SWOT Analysis
Chapter 4. Biosimilar Contract Manufacturing Market: Source Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Biosimilar Contract Manufacturing Market: Source Movement Analysis
4.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
4.4. Mammalian
4.4.1. Mammalian Market Estimates and Forecasts, 2021-2033 (USD Million)
4.5. Non-mammalian
4.5.1. Non-mammalian Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 5. Biosimilar Contract Manufacturing Market: Service Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Biosimilar Contract Manufacturing Market: Service Movement Analysis
5.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
5.4. Recombinant Non-glycosylated Proteins
5.4.1. Recombinant Non-glycosylated Proteins Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5. Recombinant Glycosylated Proteins
5.5.1. Recombinant Glycosylated Proteins Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 6. Biosimilar Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Biosimilar Contract Manufacturing Market: Therapeutic Area Movement Analysis
6.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5. Blood Disorders
6.5.1. Blood Disorders Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6. Growth Hormonal Deficiency
6.6.1. Growth Hormonal Deficiency Market Estimates and Forecasts, 2021-2033 (USD Million)
6.7. Chronic & Autoimmune Disorders
6.7.1. Chronic & Autoimmune Disorders Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8. Rheumatoid Arthritis
6.8.1. Rheumatoid Arthritis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.9. Others
6.9.1. Others Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 7. Biosimilar Contract Manufacturing Market: Regional Estimates & Trend Analysis
7.1. Regional Outlook
7.2. Biosimilar Contract Manufacturing Market: Regional Movement Analysis
7.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Region, 2021-2033 (USD Million)
7.4. North America
7.4.1. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5. Europe
7.5.1. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Framework
7.5.8.4. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Framework
7.5.9.4. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6. Asia-Pacific
7.6.1. Asia-Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Framework
7.6.7.4. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7. Latin America
7.7.1. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8. Middle East & Africa
7.8.1. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Framework
7.8.5.4. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.6. Oman
7.8.6.1. Key Country Dynamics
7.8.6.2. Competitive Scenario
7.8.6.3. Regulatory Framework
7.8.6.4. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.7. Qatar
7.8.7.1. Key Country Dynamics
7.8.7.2. Competitive Scenario
7.8.7.3. Regulatory Framework
7.8.7.4. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.1.1. Market Leaders
8.1.2. Emerging Players
8.2. Company Market Assessment Analysis, 2024 (Company Heat Map Analysis)
8.3. Key Company Profiles
8.3.1. Boehringer Ingelheim GmbH
8.3.1.1. Company Overview
8.3.1.2. Financial Performance
8.3.1.3. Product Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Lonza
8.3.2.1. Company Overview
8.3.2.2. Financial Performance
8.3.2.3. Product Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. Rentschler Biopharma SE
8.3.3.1. Company Overview
8.3.3.2. Financial Performance
8.3.3.3. Product Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. AGC Biologics
8.3.4.1. Company Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. ProBioGen
8.3.5.1. Company Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. FUJIFILM Diosynth Biotechnologies
8.3.6.1. Company Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. Toyobo Co. Ltd.
8.3.7.1. Company Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Samsung Biologics
8.3.8.1. Company Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Thermo Fisher Scientific, Inc.
8.3.9.1. Company Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Binex Co., Ltd.
8.3.10.1. Company Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives
8.3.11. WuXi Biologics
8.3.11.1. Company Overview
8.3.11.2. Financial Performance
8.3.11.3. Product Benchmarking
8.3.11.4. Strategic Initiatives
8.3.12. AbbVie, Inc.
8.3.12.1. Company Overview
8.3.12.2. Financial Performance
8.3.12.3. Product Benchmarking
8.3.12.4. Strategic Initiatives
8.3.13. ADMA Biologics, Inc.
8.3.13.1. Company Overview
8.3.13.2. Financial Performance
8.3.13.3. Product Benchmarking
8.3.13.4. Strategic Initiatives
8.3.14. Catalent, Inc
8.3.14.1. Company Overview
8.3.14.2. Financial Performance
8.3.14.3. Product Benchmarking
8.3.14.4. Strategic Initiatives
8.3.15. Cambrex Corporation
8.3.15.1. Company Overview
8.3.15.2. Financial Performance
8.3.15.3. Product Benchmarking
8.3.15.4. Strategic Initiatives
8.3.16. Pfizer Inc.
8.3.16.1. Company Overview
8.3.16.2. Financial Performance
8.3.16.3. Product Benchmarking
8.3.16.4. Strategic Initiatives
8.3.17. Siegfried Holding AG
8.3.17.1. Company Overview
8.3.17.2. Financial Performance
8.3.17.3. Product Benchmarking
8.3.17.4. Strategic Initiatives
List of Tables
Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 4. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, Therapeutic Area, 2021-2033 (USD Million)
Table 5. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 6. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Region, 2021-2033 (USD Million)
Table 7. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
Table 8. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 9. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 10. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 11. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 12. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 13. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 14. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 15. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 16. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 17. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 18. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 19. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 20. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
Table 21. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 22. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 23. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 24. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 25. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 26. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 27. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 28. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 29. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 30. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 31. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 32. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 33. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 34. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 35. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 36. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 37. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 38. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 39. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 40. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 41. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 42. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 43. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 44. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 45. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 46. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 47. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 48. Asia-Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
Table 49. Asia-Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 50. Asia-Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 51. Asia-Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 52. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 53. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 54. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 55. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 56. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 57. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 58. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 59. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 60. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 61. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 62. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 63. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 64. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 65. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 66. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 67. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 68. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 69. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 70. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
Table 71. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 72. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 73. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 74. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 75. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 76. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 77. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 78. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 79. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 80. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
Table 81. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 82. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 83. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 84. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 85. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 86. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 87. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 88. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 89. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 90. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 91. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 92. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 93. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 94. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 95. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 96. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 97. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 98. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
Table 99. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021-2033 (USD Million)
Table 100. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021-2033 (USD Million)
Table 101. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021-2033 (USD Million)
List of Figures
Figure 1 Biosimilar contract manufacturing market segmentation
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market dynamics
Figure 9 Market driver analysis (current & future impact)
Figure 10 Market restraint analysis (current & future impact)
Figure 11 Porter’s five forces analysis
Figure 12 PESTEL by SWOT analysis
Figure 13 Biosimilar contract manufacturing source key takeaways (USD Million)
Figure 14 Biosimilar contract manufacturing market: Source, market share 2024 & 2033
Figure 15 Mammalian biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 16 Non-mammalian biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 17 Biosimilar contract manufacturing therapeutic area key takeaways (USD Million)
Figure 18 Biosimilar contract manufacturing market: therapeutic area, market share 2024 & 2033
Figure 19 Oncology biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 20 Blood disorders biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 21 Growth hormonal deficiency biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 22 Chronic & autoimmune disorders biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 23 Rheumatoid arthritis biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 24 Others biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 25 Biosimilar contract manufacturing service key takeaways (USD Million)
Figure 26 Biosimilar contract manufacturing market: service, market share 2024 & 2033
Figure 27 Recombinant non-glycosylated proteins biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 28 Recombinant glycosylated proteins biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 29 Regional outlook, 2024 & 2033
Figure 30 North America biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 31 U.S. biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 32 Canada biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 33 Mexico biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 34 Europe biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 35 UK biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 36 Germany biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 37 France biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 38 Italy biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 39 Spain biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 40 Denmark biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 41 Sweden biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 42 Norway biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 43 Asia-Pacific biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 44 Japan biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 45 China biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 46 India biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 47 Australia biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 48 South Korea biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 49 Thailand biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 50 Latin America biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 51 Brazil biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 52 Argentina biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 53 MEA biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 54 South Africa biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 55 Saudi Arabia biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 56 UAE biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 57 Kuwait biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 58 Qatar biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)
Figure 59 Oman biosimilar contract manufacturing market estimates and forecasts, 2021-2033 (USD Million)

Companies Mentioned

The leading players profiled in this Biosimilar Contract Manufacturing market report include:
  • oehringer Ingelheim GmbH
  • onza
  • atalent, Inc.
  • entschler Biopharma SE
  • GC Biologics
  • roBioGen
  • UJIFILM Diosynth Biotechnologies
  • oyobo Co. Ltd.
  • amsung Biologics
  • hermo Fisher Scientific, Inc.
  • inex Co., Ltd.
  • uXi Biologics
  • bbVie, Inc.
  • DMA Biologics, Inc.
  • ambrex Corporation
  • fizer Inc.
  • iegfried Holding AG

Table Information

Report AttributeDetails
No. of Pages180
PublishedSeptember 2025
Forecast Period2025 - 2033
Estimated Market Value ( USD ) in 2025 $ 8.91 Billion
Forecasted Market Value ( USD ) by 2033 $ 25.19 Billion
Compound Annual Growth Rate13.8%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Europe Biosimilar Market Report 2025-2033 - Product Image

Europe Biosimilar Market Report 2025-2033

  • Report
  • 126 Pages
  • Europe
From
Biosimilar Market Report 2025-2033 - Product Image

Biosimilar Market Report 2025-2033

  • Report
  • 123 Pages
  • Global
From
Biosimilar Contract Manufacturing Market - Global Outlook & Forecast 2022-2027 - Product Image

Biosimilar Contract Manufacturing Market - Global Outlook & Forecast 2022-2027

  • Report
  • 306 Pages
  • Global
From
Biosimilars Market Industry Trends and Global Forecasts to 2035 - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players - Product Image

Biosimilars Market Industry Trends and Global Forecasts to 2035 - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players

  • Report
  • 319 Pages
  • Global
From
Oncology Biosimilars Market Report by Drug Type, and Region 2025-2033 - Product Image

Oncology Biosimilars Market Report by Drug Type, and Region 2025-2033

  • Report
  • 140 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.